Universal CAR-T Cell Production Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Universal CAR-T cell therapies are expected to transform the landscape of cancer immunotherapy and enhance patient results. Creative Biolabs has earned a strong reputation in the field of cellular and gene therapy research, innovation, and advancement. Our team of specialists is committed to advancing novel therapeutic solutions for UCAR-T production aimed at addressing a wide range of cancer types.

Services at Creative Biolabs

Our Universal CAR-T Cell Production Service follows a streamlined workflow that maximizes efficiency and minimizes production costs. The process can be summarized as follows:

01 Numerous Cell Sources Fit Your Need

UCAR-T derived from peripheral blood mononuclear cells (PBMCs), umbilical cord blood (UCB), and renewable stem cells such as induced pluripotent stem cells (iPSCs) or embryonic stem can be produced.

02 Gene Editing Tools for Your Choice

Various gene editing methods are available, including but not limited to Transcription Activator-like Nucleases (TALEN), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9).

03 Optional Non-gene Editing Methods

UCAR-T can also be manufactured with non-gene editing methods to minimize the off-target effect induced by gene editing, with which the expression of the target genes were interfered.

04 CAR Expression

UCAR-T can also be manufactured with non-gene editing methods to minimize the off-target effect induced by gene editing, with which the expression of the target genes were interfered.

Various Editing Strategies to Enhance UCAR-T Cell Functions

We offer a range of UCAR-T cell editing strategies designed to enhance their functionality, ultimately making them more efficient at targeting and eradicating cancer cells through various approaches.

Overcoming Immunosuppression:
Enhancing the ability to counteract immunosuppression in the tumor microenvironment by disrupting PD-1.
Downregulating transforming growth factor-β (TGFβ) signaling.
Introducing a PD-1-CD28 chimeric expression to boost immune response.
Improved Homing:
Augmenting the homing capabilities of UCAR-T cells through the expression of chemokine receptors like CCR2B and CXCR2.
Increasing tumor penetration through the expression of enzymes like heparanase.
Enhanced Potency:
Boosting the potency of UCAR-T cells by enabling them to secrete cytokines such as IL-12, IL-18, IL-15, and IL-7.

Customization for Different Cancers

Our service offers customization of Universal CAR-T cells for various cancer types. Whether it's hematologic malignancies like leukemia or solid tumors like breast cancer, our team can adapt the Universal CAR-T cells to target the specific antigens associated with the disease.

Please do not hesitate to contact us if you have any questions about the process.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION